Alaunos Therapeutics (TCRT) Current Assets (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Current Assets came in at $970000.0 in Q1 2026, down 9.09% YoY from $1.1 million in Q1 2025, and down 51.21% on a QoQ basis from $2.0 million in Q4 2025.
Alaunos Therapeutics (TCRT) Current Assets (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Current Assets data on file, last reported at $970000.0 in Q1 2026.
- Quarterly Current Assets fell 9.09% year-over-year to $970000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $970000.0 (down 9.09% YoY) and the FY2025 annual result came in at $2.0 million, down 27.84% from the prior year.
- Current Assets declined to $970000.0 in Q1 2026, from $2.0 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $69.8 million in Q1 2022 to a low of $970000.0 in Q1 2026.
- A 5-year average of $20.4 million and a median of $6.0 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets sank 84.64% — and 2026, when it declined 9.09%.
- Tracing TCRT's Current Assets over 5 years: stood at $53.8 million in 2022, then slumped by 84.64% to $8.3 million in 2023, then slumped by 66.65% to $2.8 million in 2024, then slipped by 27.84% to $2.0 million in 2025, then sank by 51.21% to $970000.0 in 2026.
- The last three Current Assets figures came in at $970000.0 (Q1 2026), $2.0 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | 666,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 970,000.00 |
| Dec 31, 2025 | 1.99 Mn |
| Sep 30, 2025 | 2.69 Mn |
| Jun 30, 2025 | 3.74 Mn |
| Mar 31, 2025 | 1.07 Mn |
| Dec 31, 2024 | 2.76 Mn |
| Sep 30, 2024 | 3.55 Mn |
| Jun 30, 2024 | 4.68 Mn |
| Mar 31, 2024 | 6.04 Mn |
| Dec 31, 2023 | 8.26 Mn |
| Sep 30, 2023 | 12.87 Mn |
| Jun 30, 2023 | 18.78 Mn |
| Mar 31, 2023 | 38.18 Mn |
| Dec 31, 2022 | 53.80 Mn |
| Sep 30, 2022 | 55.51 Mn |
| Jun 30, 2022 | 61.36 Mn |
| Mar 31, 2022 | 69.77 Mn |
| Dec 31, 2021 | 78.83 Mn |
| Sep 30, 2021 | 96.55 Mn |
| Jun 30, 2021 | 89.41 Mn |